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 As higher level in terms of geo-political integration policy making goes as larger the 
impact of policies and consequently benefi ts and hazards related to policies can be. In 
the globalized world nations states give up their policy making roles on certain areas of 
policy making to higher, international or transnational level of policy making. Therefore 
a policy risk assessment tool should be able to assess risks related to such international 
or transnational policies and strategies. Previous chapters of this book described devel-
opment of RAPID guidance both top-down and bottom-up methodology on level of 
national policies. This sub-chapter is going to discuss testing of the top-down RAPID 
guidance on level of a European Union (EU) policy. The EU Health Strategy 2008–
2013 “Together for health” was subjected to the assessment after a negotiation process 
with the Executive Agency for Health and Consumers (EAHC) and the Directorate for 
Health and Consumer Protection (DG SANCO) of the European Commission. 
 The main objective of testing the developed policy risk assessment tool on a real 
case on international level was to identify weaknesses and missing elements which 
could be applicable on international level, but not necessarily relevant on national level 
policies. After interview with DG SANCO colleagues, the project group underwent an 
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intensive discussion process to conduct the assessment. The different approaches 
refl ected the aim to test applicability of the RAPID guidance on international level. 
 Implementation is always one of key factors to infl uence achievements of policies; 
in case of international policies even more. If implementation is not defi ned in a policy 
or strategy it is unlikely any change will be achieved. Lack of implementation mecha-
nisms, tools, methods, is therefore a kind of hazard to question potential achievements 
of any policy. On policy level therefore more questions about implementation were 
added into RAPID guidance tool. It is important to describe in depth who is in charge 
for implementation both on international and national level; targets groups of imple-
menters must be part of a policy in the same way as target group for action and impact. 
Target groups for implementation and impact are in most cases different; in case of the 
implementation it is mostly staff of Ministries of health, who is a target group whereas 
as of impact the Health strategy claims the EU citizen as a target group. Similar as 
implementation information upon monitoring and evaluation should be assessed on 
policy level within a policy risk assessment. Lack of measurable goals, lack of indica-
tors and a monitoring system can questions achievements of a policy. 
 Assessment of the EC Health Strategy as Whole Document 
 Complex policies can be assessed as of health risks and impacts either as a whole or 
by specifi c objectives. The present assessment shows how to analyze the EC Health 
Strategy as a whole—by means of the RAPID tool. A main part of the RAPID 
methodology is the defi nition, inclusion and prioritization of health outcomes, risk 
factors and health determinants. The EC Health Strategy includes nearly all health 
outcomes even if only a few of them are specifi cally defi ned (see Table  6.1 ).
 The risk factors and resources mentioned in the strategy are nearly covering all 
determinants of health. Especially in objective 1 “key issues” to tackle are listed 
which include most health relevant risk factors or determinants: “ Healthy ageing 
must be supported by actions to promote health and prevent disease throughout the 
lifespan by tackling key issues including poor nutrition, physical activity, alcohol, 
drugs and tobacco consumption, environmental risks, traffi c accidents, and accidents 
in the home ” (EC  2007 , p. 7). 
 This makes it diffi cult to include or exclude risk factors and health outcomes 
only on the basis of the Strategy. Therefore we decided to identify the most relevant 
health outcomes for Europe in general (share of Burden of Disease—BoD) and the 
current attributable fraction of BoD for risk factors mentioned in the EC strategy. 
 Table 6.1  Health outcomes mentioned in the EC Health Strategy 
 Health outcome  Where to fi nd in EC health strategy 
 Specifi c diseases including genetic disorders  Objective 1 
 Alzheimer’s  Objective 1 
 Injuries  Objective 2 
 Communicable diseases  Objective 2 
 Specifi c diseases  Objective 2 
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This overview is presented in following sub-chapters, using the indicators healthy life 
years (HLY) and disability-adjusted life year (DALY). Additionally, the Burden of 
Disease studies of WHO were used to identify the most important risk within EU-27. 
Based on this overview it is possible to examine to what extent the EC Health Strategy 
can contribute to reduce the differences between EU-27 countries for two main health 
indicators (HLY and DALY) and to exploit the full potential health gains. 
 Distribution of Diseases Within Europe 
 To assess the potential health gains of the EU Health Strategy it is important to have 
an overview of the distribution of diseases within Europe. 
 Healthy Life Years (HLY) in EU-27 
 The indicator Healthy Life Years (HLY) was used to compare EU-27 countries. 
HLY are the “ expected remaining years lived from a particular age without long- 
term activity limitation ”. HLY “ takes into account both mortality and ill-health, 
providing more information on burden of diseases in the population than life expec-
tancy alone ” (EC, Heidi Data Tool,  http://ec.europa.eu/health/indicators/indicators/
index_en.htm ). 
 Here the HLY at birth is used. For 2008 we see large differences in healthy life 
expectancy between the EU-27 countries (see Fig.  6.1 ).
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 Fig. 6.1  Healthy life years at birth (HLY) in the EU-27 countries 2008 (own illustration, data 
adapted from the HEIDI Data Tool) 
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 Regarding potential maximum health gains, we compare the “best” and the 
“worst” countries (see Table  6.2 ).
 Disability-Adjusted Life Years (DALY) in EU-27 
 One of the most extensive studies is the WHO Global Burden of Disease Study 
(WHO GBD). It measures burden of disease using the disability-adjusted life year 
(DALY). DALY is a time-based measure and combines years of life lost due to 
premature mortality (YLL) and years of life lost due to time lived in states of less 
than full health (YLD) ( WHO  2008a ,  b ) (Fig.  6.2 ).
 WHO GBD covers more than 100 diseases (defi ned by ICD code). These diseases 
are divided into three main categories: (1)  communicable, maternal, perinatal and 
nutritional conditions (includes 39 defi ned diseases) ; (2)  non-communicable diseases 
(includes 57 diseases) and (3)  injuries (includes 9 causes of injuries) . 
 An initial comparison of DALY rates (DALY per 100,000 population) shows that 
the  non-communicable diseases play the most important role regarding the burden 
 Table 6.2  Highest and lowest healthy life years (HLY) of EC-27 countries 
 Country  HLY—men 2008  HLY—women 2008 
 Sweden  69.2  – 
 Latvia  51.5  – 
 Malta  –  71.9 
 Slovakia  –  52.3 
 Difference = Potential health gain  17.7  19.6 
Box 1: The disability-adjusted life year
The disability-adjusted life year (DALY) extends the concept of potential years of life lost due to premature death to include
equivalent years of “healthy” life lost by virtue of being in states of poor health or disability (3). One DALY can be thought of
as one lost year of “healthy” life, and the burden of disease can be thought of as a measurement of the gap between current
health status and an ideal situation where everyone lives into old age, free of disease and disability.
DALYs for a disease or injury cause are calculated as the sum of the years of life lost due to premature mortality (YLL) in the
population and the years lost due to disability (YLD) for incident cases of the disease or injury. YLL are calculated from the
number of deaths at each age multiplied by a global standard life expectancy for each age. YLD for a particular cause in a
particular time period are estimated as follows:
YLD = number of incident cases in that period × average duration of the disease × weight factor
The weight factor reflects the severity of the disease on a scale from 0 (perfect health) to 1 (death). The weights used for the
GBD 2004 are listed in Annex Table A6 of Mathers et al. (11).
In the standard DALYs reported here and in recent world Health Reports, calculations of YLL and YLD used an additional 3%
time discounting and non-uniform age weights that give less weight to years lived at young and older ages (6). Using dis-
counting and age weights, a death in infancy corresponds to 33 DALYs, and deaths at ages 5-20 years to around 36 DALYs.
 Fig. 6.2  Defi nition of the DALY indicator (WHO  2008a ,  b ) 
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of disease in Europe. In all countries of EU-27 they account for 80–90 % of the 
whole burden of disease in this country (Table  6.3 ).
 Regarding possible health gains, we compare again the “best” and the “worst” 
countries. The “best” country, Malta has 11,141 DALY per 100,000 population for 
all causes. The country with the “worst” DALY rate, Latvia, has 19,615 DALY per 
100,000 population for all causes. The difference between these two values is 8,474 
DALY per 100,000 population (all causes) and can be interpreted as potential health 
gain (see Table  6.4 ).
 To explore where the health gains can be reached concretely we need to have a 
closer look on specifi c diseases or disease categories. The three main categories of 
BoD-studies (c ommunicable, maternal, perinatal and nutritional conditions; non- 
communicable diseases and  injuries are further divided into 2–14 subcategories). 
 Table 6.3  DALY rates (DALY per 100,000 population by cause, WHO  2009 ) 
 EU27 
 DALY rate 
all causes 
 Communicable, 
maternal, perinatal and 
nutritional conditions 
 Non-communicable 
diseases  Injuries 
 Austria  12,069  495  10,583  990 
 Belgium  12,948  543  11,239  1,166 
 Bulgaria  18,296  943  16,044  1,308 
 Cyprus  12,010  833  10,275  902 
 Czech Republic  14,326  526  12,378  1,422 
 Denmark  13,447  486  11,971  990 
 Estonia  18,900  1,183  14,649  3,068 
 Finland  13,205  504  10,981  1,720 
 France  12,262  579  10,517  1,167 
 Germany  12,536  488  11,312  736 
 Greece  11,826  495  10,404  928 
 Hungary  17,941  693  15,688  1,560 
 Ireland  11,692  653  10,155  884 
 Italy  11,245  495  9,984  766 
 Latvia  19,615  1,150  15,341  3,125 
 Lithuania  18,401  1,090  13,861  3,450 
 Luxembourg  12,341  670  10,452  1,219 
 Malta  11,141  600  9,875  666 
 The Netherlands  11,486  578  10,294  614 
 Poland  14,911  699  12,454  1,759 
 Portugal  13,615  923  11,582  1,110 
 Romania  17,685  1,447  14,450  1,788 
 Slovakia  15,340  767  12,978  1,595 
 Slovenia  14,002  552  11,929  1,521 
 Spain  11,352  609  9,883  860 
 Sweden  11,478  481  10,164  833 
 UK  12,871  674  11,489  708 
 ALL average  13,961  709  11,886  1,365 
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Finally, per subcategory, there are 1–16 ICD-coded diseases (or causes of 
injuries) listed. 
 Within the  non-communicable diseases three subcategories are crucial for the 
burden of disease in Europe:
 1.  Neuropsychiatric conditions. 
 2.  Cardiovascular diseases. 
 3.  Malignant neoplasms. 
 In 25 countries of EU-27 these subcategories are the fi rst, second or third impor-
tant contribution to the total DALY. Exceptional cases are Cyprus with  Sense organ 
diseases and Lithuania with  Unintentional injuries , each on the third rank (see 
Table  6.5 ).
 On average (EU-27),  malignant neoplasms account for 2,072 DALY per 100,000 
population,  neuropsychiatric conditions for 3,179 and  cardiovascular diseases for 
2,888 DALY per 100,000 population. Regarding potential health gains, we compare 
the “best” and the “worst” countries again: Cyprus has the lowest DALY rate for 
 malignant neoplasms (971) while Hungary has the highest rate (3,044). The differ-
ence between these two values (~potential health gain) is 2,073 DALY per 100,000 
population. For  neuropsychiatric conditions the “best” country is Italy (2,546), the 
“worst” Finland (3,709), the difference amounts to 1,163 DALY per 100,000 popu-
lation. For  cardiovascular diseases the DALY rate of 6,924 in Bulgaria is the high-
est and the rate of 1,415 in France is the lowest, with a difference of 5,509 DALY 
(see Table  6.6 ).
 Table 6.4  EU-27 countries with highest and lowest DALY rate 
 EU-27 countries with highest and lowest DALY  DALY rate all causes 
 High  Latvia  19,615 
 Estonia  18,900 
 Lithuania  18,401 
 Bulgaria  18,296 
 Hungary  17,941 
 Romania  17,685 
 Low  Greece  11,826 
 Ireland  11,692 
 The Netherlands  11,486 
 Sweden  11,478 
 Spain  11,352 
 Italy  11,245 
 Malta  11,141 
 1  2  3  Sum 
 Neuropsychiatric conditions  18  9  0  27 
 Cardiovascular diseases  9  11  7  27 
 Malignant neoplasms  0  7  18  25 
 Sense organ diseases  0  0  1  1 
 Unintentional injuries  0  0  1  1 
 Table 6.5  Main 
non-communicable diseases 
subcategories which 
contribute as fi rst, second or 
third importance to total 
DALY in a country 
G. Guliš et al.
239
 In the 18 countries where  neuropsychiatric conditions are the main causes of 
total DALY a closer look shows that  unipolar depressive disorders lead to the most 
DALY within this group (see Table  6.7 ).
 With the indicator HLY it is possible to get an overview of differences in health 
status between countries. The difference in HLY between the “best” (highest HLY) 
and the “worst” (lowest HLY) country can be interpreted as health gain potential: 
the highest HLY should be possible to reach for all countries; of course adequate 
measures are needed. 
 The health gain potential seems to be enormous: nearly 20 healthy life years 
seem to be possible. 
 A possible next step to assess the causes of these differences would lie in a com-
parison between policies and measures in “best” and “worst” countries. But it is not 
possible to break this indicator down into single disease or disease groups and link 
causal-effect-relationships for single risk factors to the healthy life expectancy. 
 Table 6.6  DALY rates, three major non-communicable diseases (DALY 
per 100,000 population by cause, WHO  2009 ) 
 EU27 
 Malignant 
neoplasms 
 Neuropsychiatric 
conditions 
 Cardiovascular 
diseases 
 Austria  1,882  3,211  1,828 
 Belgium  2,193  3,183  2,129 
 Bulgaria  2,162  3,166  6,924 
 Cyprus    971  2,591  2,258 
 Czech Republic  2,571  2,970  3,358 
 Denmark  2,350  3,199  2,093 
 Estonia  2,329  3,493  4,676 
 Finland  1,612  3,709  2,305 
 France  2,234  3,439  1,415 
 Germany  2,114  3,088  2,392 
 Greece  1,897  2,607  2,764 
 Hungary  3,044  3,645  4,193 
 Ireland  1,725  3,286  1,735 
 Italy  2,056  2,546  1,941 
 Latvia  2,340  3,418  5,705 
 Lithuania  2,175  3,455  4,319 
 Luxembourg  1,798  3,260  2,002 
 Malta  1,688  2,661  2,022 
 The Netherlands  2,112  3,013  1,707 
 Poland  2,368  3,229  3,245 
 Portugal  2,032  2,982  2,416 
 Romania  2,115  3,156  5,009 
 Slovakia  2,144  3,667  3,422 
 Slovenia  2,452  3,283  2,464 
 Spain  1,890  2,760  1,556 
 Sweden  1,680  3,387  2,004 
 UK  2,007  3,432  2,083 
 ALL average  2,072  3,179  2,888 
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For further assessment the indicator disability-adjusted life year (DALY) offers 
more detailed information. 
 With the DALY indicator it is possible to compare the contribution of different 
diseases to the total burden of disease in one country and between countries. So the 
DALY indicator offers more detailed information about the concrete diseases which 
lead to differences in healthy life expectancy. 
 The difference in DALY rate between the “best” (lowest DALY rate) and the 
“worst” (highest DALY rate) country could also be interpreted as health gain poten-
tial: the lowest DALY rate should be possible to reach for all countries, of course 
with adequate measures (see Table  6.8 ).
 Major Risk Factors for Health in the EU-27 Countries 
 The leading risk factor in the EU-27 is tobacco (WHO  2005 ); it is the leading cause 
of the total burden of disease expressed in DALY in 16 out of 27 countries. In the 
remaining countries tobacco is the second or third cause of the total burden of 
disease (see Table  6.9 ).
 In average tobacco accounts for 12.7 % of all DALY of a country in EU-27 
(range 5.6 %—Cyprus to 20.9 %—Hungary). The prevention potential is vast, as 
demonstrated in the Hungarian assessment in Chap.  3 . 
 Other leading risk factors are related to lifestyle, too. The top 5 in each country are 
accounting for ~50 % of all DALY. 
 Table 6.8  Potential health 
gains based on the 
comparison of HLY and 
DALY rates between EU-27 
countries 
 Health outcome  Potential health gain 
 HLY at birth for men  17.7 HLY 
 HLY at birth for women  19.6 HLY 
 All causes  8,474 DALY 
 Malignant neoplasms  2,073 DALY 
 Neuropsychiatric conditions  1,163 DALY 
 Cardiovascular diseases  5,509 DALY 
 Number of countries 
with rank 
 Neuropsychiatric conditions  1  2  3  Sum 
 Unipolar depressive disorders  18  0  0  18 
 Alzheimer and other dementias  0  10  6  16 
 Alcohol use disorders  0  7  8  15 
 Drug use disorders  0  0  2  2 
 Schizophrenia  0  1  0  1 
 Bipolar disorder  0  0  1  1 
 Migraine  0  0  1  1 
 Table 6.7  Main 
neuropsychiatric conditions 
which are the fi rst, second or 
third important cause of 
DALY in a country 
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 To What Extent can the EC Health Strategy Contribute to Tap 
the Full Potential Health Gains? 
 Based on this overview, we were able to examine to what extent the EC Health 
Strategy can contribute to reduce the differences between EU-27 countries for two 
main health indicators (HLY and DALY) and to tap the full potential health gains. 
In the fi rst three parts of this chapter the most relevant diseases for EU-27 and the 
most important risk factor were identifi ed. 
 In this fourth part of the chapter, the actions of the strategy to tackle diseases and 
risk factors are identifi ed (see Table  6.10 ).
 Number of countries, where the risk 
factor attributes to the total burden 
of disease on … 
 Risk factor  Rank 1  Rank 2  Rank 3  Sum 
 Tobacco  16  6  5  27 
 High blood pressure  4  10  7  21 
 Alcohol  7  9  4  20 
 High BMI  0  1  7  8 
 High cholesterol  0  1  4  5 
 Table 6.9  Major risk factors 
in EU-27 countries 
 Table 6.10  Strategies mentioned in the EC Health Strategy 
 No.  Actions  Objective 
 1  Measures to promote the health of older people and the workforce and actions 
on children’s and young people’s health (Commission) 
 1 
 2  Development and delivery of actions on tobacco, nutrition, alcohol, mental 
health and other broader environmental and socio-economic factors 
affecting health (Commission, Member States) 
 1 
 3  New Guidelines on Cancer screening and a Communication on European Action 
in the Field of Rare Diseases (Commission) 
 1 
 4  Follow up of the Communication on organ donation and transplantation 
(Commission) 
 1 
 5  Strengthen mechanisms for surveillance and response to health threats, 
including review of the remit of the European Centre for Disease prevention 
and Control (Commission) 
 2 
 6  Health aspects on adaptation to climate change (Commission)  2 
 7  Community framework for safe, high quality and effi cient health services 
(Commission) 
 3 
 8  Support member states and regions in managing innovation in health systems 
(Commission) 
 3 
 9  Support implementation and interoperability of e-health solutions in health 
systems (Commission) 
 3 
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 To assess the impact of these actions on health outcome we have to defi ne how 
they infl uence health determinants, risk factors and health outcomes. A problem is 
that most of the actions are not concrete enough to show these connections. As an 
example to demonstrate how the impacts of these actions could be estimated, the 
second action “Development and delivery of actions on tobacco, nutrition, alcohol, 
mental health and other broader environmental and socioeconomic factors affecting 
health” was chosen. 
 Tobacco is the major health risk factor within the EU-27. Tackling this factor 
promises the largest health gain: 6–20 % of all DALY per country. It is not very 
probable to achieve 100 % tobacco-free environments in the EU and to tap the full 
prevention potential. 
 Conclusions 
 Main objective of this assessment was to test the developed policy risk assessment 
tool (RAPID tool or methodology) on the case of EC Health Strategy. The EC 
Health Strategy is a very special case for using the RAPID tool. An important aspect 
of the RAPID tool is to assess affected health determinants, risk factors and health 
outcomes, defi ne the connections between them and prioritize. The EC Health 
Strategy includes nearly all health outcomes and health determinants, so it was very 
diffi cult to exclude and prioritize. Another diffi culty was that the Strategy included 
very broad objectives, clear aims are missing, and only a few health outcomes were 
mentioned concretely (“specifi c diseases”). 
 The approach to defi ne important diseases and risk factors using comprehen-
sive indicators like DALY and HLY was a very suitable extension of the RAPID 
tool. 
 We were able to show a large health gain potential for major diseases and 
related to major risk factors. Actions defi ned in the EC Health Strategy can con-
tribute to achieve health gains but it has to be defi ned in what extent. In general 
the potential health gains regarding actions on lifestyle risk factors can be assumed 
as very large. A possible next step in assessment could be a comparison between 
policies and measures in “best” and “worst” countries to identify reasons for 
differences. 
 We have shown the enormous health gain potential by tackling specifi c major 
diseases and tackling main risk factors. But it is the wrong conclusion to neglect 
other diseases and risk factors. For example, the communicable diseases could lead 
to a huge amount of DALY if there are outbreaks. The number of DALY might be 
very low because of existing well implemented surveillance mechanisms. On the 
other hand a low DALY rate or a small amount of DALY is not necessarily a product 
of a good prevention or treatment policy. For some diseases underreporting might 
be a cause of a low DALY rate. 
G. Guliš et al.
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 Assessment of EC Health Strategy by Specifi c Objectives 
 Four specifi c, single issue assessments were conducted on three objectives of the 
EC Health strategy:
•  Two related to “Strengthen mechanisms for surveillance and response to health 
threats, including review of the remit of the European Centre for Disease prevention 
and Control”—case of meningococcal meningitis and infl uence pandemic 
preparedness. 
•  One on “Support Member States and Regions in managing innovation in health 
systems”—cardiovascular disease mortality and morbidity. 
•  One on “Development and delivery of actions on tobacco, nutrition, alcohol, 
mental health and other broader environmental and socioeconomic factors affecting 
health”—tobacco policy. 
 In all four cases a national policy or programme was clearly linked to the EC 
Health strategy; the Slovenian public health policy, Romanian infl uenza preparedness 
plan, Polish invasive cardiology program and the Hungarian anti-tobacco legislation 
were identifi ed as national counterparts of the EC health strategy. This confi rms the 
fi nding from interviews with DG SANCO representatives on need to include different 
levels of policies into main policy step while conducting policy risk assessment of 
an international policy. 
 To integrate all the characteristics of the discussion developed previously, be 
more specifi c and facilitate the understanding of argumentation on the need of 
inclusion of different policy levels the following scheme presents all policy levels, 
target groups (European Commission and Member States), actions for the two target 
groups and specifi c infl uenza pandemic countermeasures. 
 The fi rst policy level is the EC Health Strategy followed by its second objective 
“Protecting citizens from health threats” from the two target group perspective 
(second policy level). For each of these two, using offi cial documents actions related 
to the Health Strategy Objective and specifi c pandemic infl uenza countermeasures 
and health outcomes (third and fourth policy level) were identifi ed. 
 The fi rst policy level identifi ed in the Health Strategy targets the European 
Commission in order to display the goals to be achieved by member states in respect 
of health care. 
 The second level of policy drifts from the European Commission to Member 
States. An important aspect characterizing this level consists in the fact that is bipo-
lar, catching simultaneously the European institutional level as well as member 
states health institutions. 
 The third policy level is identifi ed as the specifi c actions for each of the two 
actors of the second level. 
 The fourth policy level is the ultimate level of implementing health services 
and is drifting from the ones above it. It also represents the translation into practice 
of all the rules and principles regarding the health protection system and related to 
6 Application of RAPID Guidance on an International Policy
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both member states and European Commission apparatuses. European Commission’s 
actions of applying a mechanism of surveillance in order to prevent health threats 
imply in the fourth level of health policy a decreased prevalence of infl uenza 
pandemics. It is natural that the measures taken in order to diminish the prevalence 
of health threats at macro level to be universally available for all member states so 
as to action equally and apply the same steps in reducing the widespread of infl u-
enza pandemics. Analyzing the facts from this perspective, we can identify two 
objectives to focus on to European level: travel and trade restrictions and general 
personal hygiene. 
 Travel and trade restrictions are welcomed in case of infl uenza pandemics 
because they represent the heart of social and business activities nowadays, and the 
main measures which should be taken in case of outbreak consists of travel advice 
so as to offer information about the risks people are exposed to, entry screening to 
identify and control the infected people, borders closure to stop the widespread of 
the virus and ultimately international travel restrictions so as to block it to become 
a global issue. 
 Promoting general personal hygiene is also a feasible action, which can be put in 
practice by all the citizens of Europe. Some of the measures identifi ed in the scheme 
are part of the natural course of personal daily hygiene, consisting in hand washing 
so as to protect the human body from ingesting bacteria and respiratory hygiene. 
Other measures are focusing on protecting the citizens in case of pandemics, advising 
them to wear masks in order to prevent the contact with the virus and self- isolation 
so as to protect other people from getting the virus. 
 These are the measures proposed by Health Strategy document which may be 
applied in case of pandemic infl uenza break out, insisting on the one hand on 
prevention and providing protection for European citizens, and on the other hand on 
establishing the measures should be taken in such situation to action immediately 
and cease the illness. 
 The other aspect of the fourth policy level regarding member states is focusing on 
the implementation of the measure but at a national level. The main goal identifi ed 
is to change the incidence of pandemic infl uenza. The same pattern as in Romanian 
top-down case study, inscribing in the scheme the two measures proposed at the national 
level, namely, school closure and vaccination was followed. Adopting these two steps 
may have a great impact on the ordinary course of the society, but they are mandatory to 
prevent, control and cease a case of pandemic infl uenza at national level. 
 School closure may constitute a limitation for continuing the usual social life, 
fi rstly causing social distancing and quarantine. Even though the magnitude of such 
action could paralyze the entire social order, it is increasingly important to appeal to 
isolation and quarantine so as to separate from the healthy people and avoid infesting 
them. Workplace closure is also a manner for preventing the extent of disease, more-
over avoiding personal contact could decrease the percentage of infected people. 
Another measure taken on national level, which may have a great contribution in 
stopping pandemics, may reside in cancelling the public events. 
 Starting a vaccination campaign could be the most preventive achievement in 
order to assure and shelter population’s health. Furthermore, surveillance for prisons 
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and elderly homes, prophylaxis and animal and bird surveillance for thwarting the 
transmission of the virus from animals to human beings should be included. 
 The four health policy levels are functioning after top-down mechanism; policy 
content is translated into practice on the one hand, at member states level by vacci-
nation campaign and school closure and on the other hand at European level by 
promoting general personal hygiene notions and by asserting travel and trade 
restrictions. 
 The main objective of the detailed explanation of the scheme delivered below 
lies in the attempt to offer a justifi cation for strengthening the role and the implica-
tion of the European Commission in managing situations involving pandemics 
(Together for Health: A Strategic Approach for the EU 2008–2013,  2007 ).
 
EC Health Strategy 1
st Policy
Level
European Commission Member States Policy
LevelEuropean Commission, Council of the EU, ECDC, WHO, WHO Europe
official documents Romanian National Plan for interventions in Influenza Pandemics
Surveillance of health threats 3rd
Mechanisms of surveillance / response Development and delivery of actions on surveillance / response
Lower prevalence of influenza pandemics Change in incidence of pandemic  influenza 4
th Policy
Level
School closure Vaccination
Travel and trade re-
strictions
Social distancing and
quarantine Community infection control
Hand washing Travel advice Isolation and quarantine Prison and elderly homes sur-
veillance
Mask wearing Entry screening Workplace closure Prophylaxis
Respiratory hygiene Borders closure Avoid personal contact Animals and birds surveillance
Self-isolation International travel re-
strictions
Cancel public events
2nd
General personal
hygiene
Policy
Level
 
 From Policy to Level of Determinants of Health is Crucial 
 The determinants were selected upon literature review and discussion process. 
 Determinants of health are infl uencing each other so the top down model is rather 
a circle or loop model. Therefore one policy with just one positive impact on one 
determinant is likely to launch a chain reaction on few determinants and the other 
way around. The assessment of surveillance of meningococcal meningitis illus-
trated well the “circle or loop mechanism.” 
 Strengthened surveillance mechanisms and response to health threads would 
have positive impact on socio-economic status, which is one of the most important 
socio-economic determinant and that infl uences public health. Socio-economic 
determinants of health (for example housing conditions) have strong impact on the 
environmental determinant of health (for example indoor environment). Poor and 
less affl uent population groups tend to be more often affected by inadequate housing 
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conditions and higher environmental burden in their residential environments. 
Social status and low income is strongly associated with increased exposure to 
environmental risks in the private home or related to residential location. Living and 
housing conditions are the basis of many factors infl uencing easier transmission of 
meningococcal. Epidemiological fi ndings suggest strong associations between 
housing conditions and health effects. Social status has impact on the behavioural 
and personal determinants of health. It is known that smoking and excessive drink-
ing is more common among less affl uent people. 
 This process must be considered while doing policy risk assessment and has 
been included into RAPID guidance tool. 
 Another important issue to consider for assessment of policies on international 
level could be the differences regarding the economic development. The differences 
between EU member states are involving different pathways of applying the policy. 
These differences could contribute at improving interrelations between European 
countries so as to maintain permanent communication and regulate the implementa-
tion process in order to equally put the policy in practice. The process of applying 
the policy could encounter diffi culties because of the dissimilarities regarding the 
Member States healthcare systems and also, the national economical contribution 
due to the variance of state budget income. Availability and accessibility of appro-
priate methods and mechanisms does differ by health care systems and needs to be 
considered also as part of assessment as the cardiologic treatment methods assess-
ment has shown. 
 Time is another important factor to consider while doing risk assessment of 
international (and any) policies. Depending on type of the health effect the time 
period needs to take in account not only the known latency period (onset of expo-
sure to onset of disease) but also the time period form development of a policy to its 
full implementation. Changes in determinants of health and consequently risk factors 
occur only after a policy is fully implemented delaying so the onset of exposure. 
It is rather rare that short term effects could be seen in the immediate period of time 
(1–2 weeks) from applying the policy because the urgent character demanded by its 
content and, most often long term effects could be observed at institutional level 
after a longer period of time (1 year). Time period is extremely relevant in cases like 
the tobacco policy for example. 
 In the study, the health impact of the tobacco tax policy was evaluated applying 
integrated quantitative impact assessment. The full impact structure of the hypoth-
esized policy action of increasing price of tobacco products by 10 % was mapped. 
Infl uenced health determinants, risk factors and health outcomes were identifi ed 
and prioritized so as to select one causal chain of high importance for detailed 
quantitative assessment. In this process, the guidance provided by the method-
ological tool developed in a previous phase of the RAPID project was used and 
found to be applicable for the task. 
 The selected impact chain included substance use as determinant, active smoking 
as risk factor and lung cancer as health outcome. Quantitative exposure and outcome 
assessment was found feasible for the selected causal pathway. The study used −0.5 
and −0.34 price elasticity that is 5 and 3.4 % reduction in tobacco use induced by 
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10 % price increase among males and females, respectively. The calculated measure 
was attributable death determined for the baseline and the projected scenario after 
the price increase. The difference, perceived as the health gain of the policy 
measure, was calculated to be 12,326 lives (7,668 among males and 4,658 among 
females) that can be saved annually as a result of increasing tobacco prices by 10 % 
in all member states of the European Union. 
 The health consequences of tobacco smoking pose a high burden on the European 
population, especially in older age groups, since smoking-related diseases of public 
health importance are typically chronic conditions that need long lag phase for 
development. Therefore, the importance of tackling the issue of smoking becomes 
more and more evident in an aging population. The inclusion of smoking into the 
First objective “Fostering good health in an aging Europe” of the EU Health 
Strategy, as a factor to be dealt with, is supported by the fi nding of this study. 
The selected tobacco policy proved to be effective measure providing example for 
how to manage the public health problem caused by smoking in the European popu-
lation in the future. 
 In the study, quantitative assessment was integrated in the policy health impact 
assessment process in a structured way and proved to be feasible for four health 
outcomes that are diseases of high public health priority. Full chain approach and 
prioritization on each level of the impact chain proved to be essential for systematic 
quantifi cation and the followed guidance provided valuable help in this process. 
Some diffi culties were noted in the consistent rigid separation of health determi-
nants and risk factors that can be hardly discussed in an isolated way in some cases. 
It has also been pointed out that those who intend to use the guidance with limited 
previous practice in health impact assessment may fi nd the methodological instruc-
tions (How to do) insuffi cient. In spite of the noted shortcomings of the applied 
tool, the demonstrated methodology offers a practicable example for using quanti-
tative assessment integrated in the health impact assessment of policies carried out 
on EU level. 
 Discussion of the Risk Assessment Process 
 The RAPID guidance proved to be a useful tool to assess potential risks related to 
EC Health strategy. The guidance allowed identifying major hazards and outlining 
possible impacts (in selected cases lead to quantifi cation of impact). It seems to be 
obvious that a full chain policy risk assessment using the RAPID guidance needs 
to combine these approaches; the policy level could be described by risk assess-
ment approach, yet quantifi cation of risks need more work. For practice even 
identifi cation of hazards, which might question success of policy in terms of its 
impact, is a positive phenomenon. The remaining three levels, determinants of 
health, risk factors and health effect, could be assessed by more impact assessment 
methodology. 
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